IGM Biosciences Inc（IGMS）资讯与事件IGMSIGM Biosciences Inc

IGM Biosciences be acquired by Concentra for $1.247 in cash per share

IGM Biosciences announced that it has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock, plus one non-tradeable contingent value right, CVR, which represents the right to receive: 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences' product candidates and intellectual property that occurs within one year following closing, each pursuant to a contingent value rights agreement. The IGM Biosciences Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all IGM Biosciences stockholders and has approved the Merger Agreement and related transactions.

IGM Biosciences reducing workforce by 73%, evaluating strategic alternatives

IGM Biosciences announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. The company is currently evaluating internal options as well as potential strategic alternatives with the goal of maximizing value for its shareholders. While this internal evaluation and strategic exploration are ongoing, the company is immediately taking steps, including an approximately 73% reduction in force, to preserve cash. The company reported cash and investments of approximately $183.8M unaudited as of December 31, 2024. "I want to thank our colleagues who will be departing from IGM as part of the restructuring and acknowledge their many contributions to our programs. We are grateful for their support and wish them all the best in their future endeavors," said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences.

IGM Biosciences halting further development of imvotamab and IGM-2644

IGM Biosciences announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. "Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success. Due to these findings, we have decided to discontinue further development of imvotamab. I would like to thank the patients and investigators who have participated in the imvotamab clinical studies as well as our employees for their commitment to transforming the lives of patients living with autoimmune diseases. Concurrent with discontinuation of the imvotamab program, IGM-2644 is also being terminated due to strategic considerations," said Mary Beth Harler, M.D., Chief Executive Officer of IGM Biosciences.